|
Genes to Cells IWAI et Al. (Al-Alwan et al., 2007; Marshall et al., 2002) . FDC-SP is also expressed in the parotid gland, periodontal ligament and junctional epithelium (JE) having similar molecular properties to saliva proteins, statherin and histatin, suggesting it could have an antibacterial activity function (Dodds, Johnson, & Yeh, 2005; Oshiro et al., 2012; Shinomura et al., 2008) . Several studies show that over-expression of FDC-SP in periodontal ligament cells could keep fibroblastic character, inhibit osteogenic differentiation and enhance osteoclastogenesis (Liu, Bian, Ding, Chi, & Wang, 2016; Wei et al., 2011; Xiang, Ma, He, Wei, & Gong, 2013 .
JE is the stratified nonkeratinizing epithelium that surrounds the tooth like a collar and is the base of the gingival sulcus attached to the tooth enamel. Tooth enamel and internal basal lamina of JE are bound to each other by hemidesmosome (Hormia, Owaribe, & Virtanen, 2001) . It is important for the host defense against periodontopathic bacteria and for periodontal protection (Nakayama et al., 2014 (Nakayama et al., , 2016 Oshiro et al., 2012) . As a complex response to bacterial challenge, JE secretes various cytokines and chemokines and activates the immune defense system. FDC-SP in the JE is temporarily decreased in experimental periodontitis (Oshiro et al., 2012; Takahashi et al., 2014) . Thus, the study of FDC-SP in the JE and periodontal ligament may offer new insights into additional defense mechanisms in the periodontium.
To elucidate the mechanism of transcriptional regulation of human FDC-SP gene by inflammatory cytokine, we investigated the effect of tumor necrosis factor-α (TNF-α) on FDC-SP gene transcription in gingival epithelium cells.
| RESULTS

| Effects of TNF-α on FDC-SP mRNA and protein levels in Ca9-22 cells
To investigate the regulation of FDC-SP transcription by TNF-α, we carried out real-time PCR using total RNA extracted from human gingival epithelial Ca9-22 and Sa3 cells, and human parotid gland adenocarcinoma-derived epitheliallike HSY cells. First, the dose-response effect of TNF-α on the FDC-SP mRNA levels was studied by treating the Ca9-22 cells with different concentrations of TNF-α for 12 hr. TNF-α increased FDC-SP mRNA levels by dose-dependent manner and had a maximal at 10 ng/ml ( Figure 1a ). Treatment of Ca9-22 and Sa3 cells with TNF-α (10 ng/ml) up-regulated FDC-SP mRNA levels at 3 hr, reached maximum at 12 hr
F I G U R E 1 Effects of TNF-α on
FDC-SP mRNA levels in Ca9-22, Sa3 and HSY cells. (a) Dose-response effects of TNF-α on FDC-SP mRNA levels in Ca9-22 cells treated for 12 hr. (b) Ca9-22 cells were treated with or without TNF-α (10 ng/ml) for 3, 6, 12 and 24 hr. (c) Sa3 cells were treated with or without TNF-α (10 ng/ml) for 3, 6, 12 and 24 hr. (d) HSY cells were treated with or without TNF-α (10 ng/ml) for 3, 6, 12 and 24 hr. FDC-SP and GAPDH mRNA levels were measured by real-time PCR. The experiments were carried out in triplicate for each data point. Quantitative analyses of the data sets are shown with standard errors. Significantly different from control; *p < .05 and **p < .01 
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(10 ng/ml TNF-α) (10 ng/ml TNF-α) (10 ng/ml TNF-α) (ng/ml TNF-α) and then decreased at 24 hr (Figure 1b,c) . TNF-α increased AMTN mRNA levels in a time-dependent manner at 3 hr and reached maximum at 12 and 24 hr in HSY cells (Figure 1d ). TNF-α (10 ng/ml) induced FDC-SP protein expression at 3 hr and reached its maximum at 12 and 24 hr in Ca9-22 cells (Figure 2 ).
| Transient transfection analyses of human FDC-SP promoter constructs
As the effect of TNF-α likely involved transcription factor interaction in the promoter region of the human FDC-SP gene, subsequent studies were carried out. Transient transfection of chimeric constructs encompassing different regions of the human FDC-SP gene promoter ligated to a luciferase reporter gene (−116FDCSP; −116~+60, −210FDCSP; −210~+60, −345FDCSP; −345~+60, −501FDCSP; −501~+60, −717FDCSP; −717~+60, −948FDCSP; −948~+60) was carried out in Ca9-22 cells. The results of the luciferase assays indicated an increase in transcription after 12 hr of treatment with TNF-α (10 ng/ ml) in −116FDCSP to −948FDCSP (Figure 3 ). Unique sequences within the human FDC-SP gene promoter between −356 and −1 are a Yin Yang 1 (YY1; nts −69 to −53), inverted CCAAT (nts −92 to −81), GATA (nts −122 to −106), CCAAT enhancer-binding protein 1 (C/EBP1; nts −143 to −133), octamer-binding protein 1 (Oct1; nts −159 to −146), C/EBP2 (nts −194 to −181), cAMP response element (CRE; nts −224 to −213) and C/EBP3 (nts −282 to −269) elements ( Figure 4) . Next, we introduced 3-bp mutations within the −345FDCSP constructs in the YY1, GATA, C/EBP2 and C/EBP3 elements targeted by TNF-α. When we used mutation −345FDCSP constructs, luciferase activities induced by TNF-α were partially inhibited in the −345mYY1, −345mGATA, −345mC/EBP2, −345mC/EBP3 and double mutation in −345mC/EBP2 and −345mC/EBP3 (−345mC/EBP2+mC/EBP3) ( Figure 5 ). These results suggested that YY1, GATA, C/EBP2 and C/EBP3 act as functional response elements through which TNF-α regulates FDC-SP gene transcription. TNF-α-induced −345FDCSP activities were inhibited by tyrosine kinase inhibitor herbimycin A (HA; 1 μM), mitogen-activated protein kinase kinase (MEK1/2) inhibitor U0126 (5 μM) and phosphoinositide 3-kinase (PI3K) inhibitor LY249002 (10 μM). However, protein kinase C (PKC) inhibitor H7 (5 μM) could not inhibit the TNF-α-induced −345FDCSP activity ( Figure 6 ).
| Gel mobility shift assays
To identify nuclear proteins that bind to the YY1, GATA, C/EBP2 and C/EBP3 elements and mediate TNF-α effects on transcription, double-stranded oligonucleotides were Cy5-labeled and incubated with equal amounts (3 μg) of nuclear proteins extracted from confluent Ca9-22 cells that were either not treated (Control) or treated with TNF-α (10 ng/ml) for 3, 6 and 12 hr. With the nuclear extract from confluent control culture of Ca9-22 cells, shifts 
| Chromatin immunoprecipitation assays
We examined whether transcription factors are able to interact directly with the human FDC-SP gene promoter and how TNF-α influences the interactions of these transcription factors with YY1, GATA, C/EBP2 and C/EBP3. To clarify this further, we used Chromatin immunoprecipitation (ChIP) assays to examine the in vivo association of the transcription factors with YY1, GATA, C/EBP2 and C/EBP3 elements in Ca9-22 cells.
YY1, GATA and C/EBPβ interacted with a chromatin fragment containing the YY1, GATA, C/EBP2 and C/EBP3, which were increased by TNF-α (10 ng/ml) in a time-dependent manner in Ca9-22 cells ( Figure 9 ). Next, we investigated which signaling pathways can regulate YY1, GATA and C/EBPβ binding to YY1, GATA, C/EBP2 and C/EBP3 after stimulation with TNF-α, tyrosine kinase inhibitor HA, MEK1/2 inhibitor U0126 and PI3K inhibitor LY294002 were used with or without TNF-α treatment. When Ca9-22 cells were stimulated with TNF-α for 12 hr, YY1, GATA and C/EBPβ binding to YY1, GATA, C/EBP2 and C/EBP3 were almost completely inhibited by three kinase inhibitors (Figure 10 ).
| DISCUSSION
TNF-α is a typical inflammatory cytokine in the inflamed tissues and induces insulin resistance (Uysal, Wiesbrock, Marino, & Hotamisligil, 1997) . Adipocytes express high levels of TNF-α (Hotamisligil, Arner, Caro, Atkinson, & Spiegelman, 1995) , and TNF-α serum levels are increased in obese, type 2 diabetes and cancer patients (Katsuki et al., 1998; McCall, Tuckey, & Parry, 1992; Winkler et al., 1998) . Periodontitis is an inflammatory disease caused by oral bacteria around the gingival sulci, and severe periodontitis can result in destruction of periodontium, alveolar bone resorption and tooth loss (Kato, Imai, Ochiai, & Ogata, 2015) . Antimicrobial periodontal treatment decreased TNF-α serum levels in patients with chronic periodontitis (Iwamoto et al., 2001 (Iwamoto et al., , 2003 . A positive statistical correlation was detected F I G U R E 6 Effects of kinase inhibitors on transcriptional activation by TNF-α. TNF-α-induced −345FDCSP activities were inhibited by HA, U0126 and LY294002, and no effect was observed for H7. between the TNF-α concentration in the gingival crevicular fluid and the severity of periodontitis (Kurtiş et al., 2005) ).
In this study, we show that TNF-α increases human FDC-SP gene transcription temporarily after 12 hr in human gingival epithelial cells by targeting YY1, GATA, C/EBP2 and C/EBP3 elements in the human FDC-SP gene promoter. FDC-SP was identified in primary follicular dendritic cells isolated from human tonsils, having structural similarities to a saliva protein statherin. FDC-SP is also expressed by TNF-α-activated FDC-like cell lines and LPS-activated peripheral blood leukocytes, but not by B-cell lines (Marshall et al., 2002; Nakamura et al., 2005) . Statherin inhibits precipitation from supersaturated calcium phosphate solutions and stabilizes supersaturated saliva (Schlesinger & Hay, 1977) . FDC-SP expresses in the periodontal ligament and JE, and prevents mineralization of periodontal ligament and adsorbs onto the surface of enamel and cementum adjacent to JE (Nakayama et al., 2017; Shinomura et al., 2008) . FDC-SP in the JE was completely lost 3 hr after the treatment with E. coli LPS in the upper molars of rats, but the immunoreactivity was detected again after 3 days (Oshiro et al., 2012) . The expression of FDC-SP was significantly decreased concurrently with the increase in interleukin-17 (IL-17) at 5 and 7 days after the induction of experimental periodontitis, and FDC-SP levels had returned to normal at 14 and 28 days (Takahashi et al., 2014) . FDC-SP expressions were observed stronger in Porphyromonas gingivalis-infected mice at early stage. However, at the following stage, FDC-SP expression decreased due to severe inflammation by P. gingivalis. In the human gingiva, FDC-SP was widely detected at the sulcular epithelium and JE in the noninflamed gingiva. In the inflamed gingiva, localization of FDC-SP was spread into the gingival epithelium (Nakayama et al., 2017) . Thus, to elucidate the function of FDC-SP in the inflamed gingiva, we used TNF-α on FDC-SP gene transcription in gingival epithelium cells.
From transient transfection analyses, we initially located the TNF-α response region to the proximal promoter (−116 to +60) of the human FDC-SP gene (Figure 3 ), which encompasses an YY1 element (Figure 4) . Transcriptional regulation by TNF-α was partially abrogated when 3-bp mutations within the −345FDCSP constructs in the YY1, GATA, C/EBP2 and C/EBP3 ( Figure 5 ). The involvement of YY1, GATA, C/EBP2 and C/EBP3 elements is further supported by gel shift assays in which nuclear proteins that formed complexes with YY1, GATA, C/EBP2 and C/EBP3 were increased by TNF-α in Ca9-22 cells (Figure 7) . Results of competition gel shift assays confirmed YY1-, GATA-, C/EBP2-and C/EBP3-protein complex formations were specific. Interestingly, a 40-fold molar excess of C/EBP3 competes with C/EBP2-protein complex formation, whereas C/EBP2 could not compete with C/EBP3-protein complex formation (Figure 8) , suggesting that the constituents of C/EBP2-and C/EBP3-binding proteins are not same. YY1 is known to have a fundamental role in normal biologic processes such as differentiation, replication, proliferation and embryogenesis (Gordon, Akopyan, Garban, & Bonavida, 2006) . YY1 plays a critical role in promoting IL-6 transcription in rheumatoid arthritis (RA), which contributes to the inflammation of RA via stimulation of Th17 differentiation (Lin et al., 2017) . GATA transcription factors (GATA-1~6) recognize (A/T)GATA(A/G) motif, and GATA-4/5/6 are expressed in the cardiovascular system and in endoderm-derived tissues including the liver, lungs, pancreas and gut (Al-azzeh, Fegert, Blin, & Gött, 2000) . Treatment of mice with LPS led to a transient increase in GATA-6 expression in the liver which was positively correlated with the expression of hepcidin, which is up-regulated because of increased systemic iron concentrations as well as during inflammation (Bagu, Layoun, Calvé, & Santos, 2013) . C/EBPs are a family of leucine zipper transcription factors involved in the regulation of various aspects of cellular differentiation and function in a variety of tissues (Poli, 1998) . C/EBPβ was originally identified as a mediator of IL-6 signaling, binding to IL-6 response elements in the promoters of acute-phase response genes TNF, IL-8 and G-CSF. TNF-α promotes nuclear localization of C/EBPβ and C/EBPδ in response to inflammatory stress (Lekstrom-Himes & Xanthopoulos, 1998) . In this study, we show that these transcription factors play important roles in transcriptional regulation of human FDC-SP gene during the inflammation process.
Results of ChIP assays suggest that TNF-α induced human FDC-SP transcription through YY1, GATA and C/ EBPβ are targeting YY1, GATA, C/EBP2 and C/EBP3 in the human FDC-SP gene promoter (Figure 9 ). The tyrosine kinase inhibitor HA, MEK1/2 inhibitor U0126 and PI3K inhibitor LY294002 inhibited the effects of TNF-α on FDC-SP transcription (Figures 6 and 10) , suggesting that tyrosine kinase, MEK1/2 and PI3K signaling pathways are crucial for TNF-α effects on FDC-SP transcription.
In conclusion, our study has identified YY1, GATA, C/EBP2 and C/EBP3 elements in the human FDC-SP gene promoter that mediate FDC-SP transcription induced by TNF-α in gingival epithelial cells and has shown that TNF-α increased YY1, GATA and C/EBPβ binding to the YY1, GATA, C/EBP2 and C/EBP3 elements through the tyrosine kinase, MEK1/2 and PI3K pathways. Further studies are necessary to explore the precise role of FDC-SP in the JE throughout the progression of periodontitis.
| EXPERIMENTAL PROCEDURES
| Cell culture
Human gingival squamous carcinoma epithelial Ca9-22 cells and human parotid gland adenocarcinoma HSY cells or human gingival squamous cell carcinoma-derived Sa3 cells were cultured in alpha-minimum essential medium (α-MEM) or Dulbecco's Modified Eagle's Medium (DMEM) containing 10% fetal calf serum (FCS) (Wako, Tokyo Japan) at 37°C in 5% CO 2 and 95% air. The cells were grown to confluence in 60-mm culture dishes in α-MEM including 10% FCS, then cultured for 12 hr in α-MEM without FCS and stimulated with TNF-α (10 ng/ml) (Wako, Tokyo Japan). Total RNA was purified from triplicate cultures at 0, 3, 6, 12 and 24 hr after stimulation by TNF-α.
| Real-time PCR
Total RNAs were isolated using Isogen II (Wako, Tokyo, Japan) from Ca9-22, Sa3 and HSY cells and used as a template for cDNA synthesis. cDNA was prepared using the PrimeScript RT reagent kit (Takara-Bio, Tokyo Japan). Quantitative real-time PCR was carried out using FDC-SP For; 5′-GCCAGTCACTTGCCATTTCT-3′, FDC-SP Rev; 5′-GGGCAGATTCAGGTATTGGA-3′, GAPDH For; 5′-GCACCGTCAAGGCTGAGAAC-3′; GAPDH Rev; 5′-ATGGTGGTGAAGACGCCAGT-3′, using the SYBR Premix Ex Taq II in a TP800 thermal cycler dice real-time system (Takara-Bio, Tokyo, Japan). The amplification reactions were carried out in a total volume of 25 μl 2x SYBR Premix Ex Taq II (12.5 μl), 10 μM forward and reverse primers and 50 ng cDNA for FDC-SP and 10 ng for GAPDH. To reduce variability between replicates, PCR premixes containing all reagents except for cDNA were prepared and aliquoted into 0.2-ml PCR tubes. The conditions for thermal cycling were 10 s at 95°C, 40 cycles of 5 s at 95°C and 30 s at 60°C. Post-PCR melting curves confirmed the specificity of singletarget amplification, and the expression of FDC-SP relative to GAPDH was determined in triplicate.
| Western blotting
For the Western blotting analysis, cell lysates of Ca9-22 cells were separated in 12% sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis and transferred to a Hybond 0.2-μm PVDF membrane (GE Healthcare, Pittsburgh, PA, USA). The membrane was then incubated for 3 hr with anti-FDC-SP polyclonal antibody (PAB20711; Abnoba, Taipei City, Taiwan) and anti-α tubulin monoclonal antibody (sc-5286; Santa Cruz Biotechnology, Paso Robles, CA, USA). Anti-rabbit and mouse IgG peroxidase conjugated were used as the secondary antibodies (Sigma-Aldrich, St. Louis, MO, USA). Immunoreactivities were detected using Clarity™ Western ECL Blotting Substrates (Bio-Rad, Hercules, CA, USA).
| Transient transfection assays
To determine the TNF-α response regions in human FDC-SP gene promoter, we prepared chimeric constructs by ligating human FDC-SP gene promoters into luciferase reporter plasmid. Various lengths of human FDC-SP gene promoter sequences (−116FDCSP; −116~+60, −210FDCSP; −210~+60, −345FDCSP; −345~+60, −501FDCSP; −501~+60, −717FDCSP; −717~+60, −948 FDCSP; −948~+60) were prepared by PCR amplification. Then, the amplified promoter DNAs were cloned into the Sac I site of the pGL3-basic multicloning site. Mutation luciferase constructs, mutation YY1 (−345mYY1; TTgAAgATAgTG), mutation GATA (−345mGATA; AAAcGcTTcTG), mutation C/EBP2 (−345mC/EBP2; CAATGtAtCAgCAA), mutation C/EBP3 (−353mC/EBP3; GCTTcGtAATgGGT) and double mutation in C/EBP2 and C/EBP3 (−353mC/ EBP2+mC/EBP3) were made using the QuickChange Sitedirected Mutagenesis Kit (Stratagene, La Jolla, CA, USA) within the context of the homologous −345~+60 FDC-SP promoter fragments. All constructs were sequenced as described previously to verify the fidelity of the mutagenesis.
Exponentially growing Ca9-22 cells were used for transient transfection assays. Twenty-four hours after plating, cells at 60%-70% confluence were transfected using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA). The transfection mixture included 1 μg of a luciferase (LUC) plasmid and 2 μg of β-galactosidase (β-Gal) plasmid (Promega, Madison, WI, USA) as an internal transfection control. β-Gal activities were determined separately to normalize the LUC activities. Two days after transfection, the cells were cultured in α-MEM without FCS for 12 hr and then stimulated with TNF-α (10 ng/ml) for 12 rh before harvest. The luciferase activities were measured using a luminescence reader (AcuuFlex Lumi 400; Aloka, Tokyo, Japan). PKC inhibitor H7 (5 μM), tyrosine kinase inhibitor HA (1 μM), MEK1/2 inhibitor U0126 (5 μM) and PI3K inhibitor LY249002 (10 μM) were used for inhibition of protein kinases.
| Gel shift analyses
Confluent Ca9-22 cells were stimulated by TNF-α (10 ng/ ml) for 0, 3, 6 and 12 hr in α-MEM without FCS and were
Genes to Cells
subsequently used to prepare the nuclear extracts. Doublestranded oligonucleotides encompassing the 5′-Cy5-labeled YY1, GATA, C/EBP2 and C/EBP3 sequences in the human FDC-SP gene promoter were prepared. Nuclear proteins (3 μg) were incubated for 20 min at room temperature (RT) with 2 pM Cy5-labeled double-stranded oligonucleotide in buffer containing 50 mM KCl, 0.5 mM EDTA, 10 mM TrisHCl (pH 7.9), 1 mM dithiothreitol, 0.04% Nonidet P-40, 5% glycerol and 1 μg of poly(dIdC). After incubation, the DNAprotein complexes were separated by electrophoresis in 5% nondenaturing acrylamide gels run at 200 V at RT. After electrophoresis, the gels were scanned using a Typhoon TRIO+ Variable Mode Imager (GE Healthcare). For competition experiments, 40-fold molar unlabeled oligonucleotides of YY1, GATA, C/EBP2 and C/EBP3 were used. The double-stranded oligonucleotide sequences were as follows: YY1 For; 5′-CC AATTTCAACATATTGAGATAGTTGA-3′, YY1 Rev; 5′-GATCTCAACTATCTCAATATGTTGAAATTG-3′, GATA For; 5′-CCACAAAAGATTTTGGTATTTA-3′, GATA Rev; 5′-GATCTAAATACCAAAATCTTTTGTG-3′, C/EBP2 For; 5′-CGTAGACCAATGGAGCAACAACATGTA-3′, C/ EBP2 Rev; 5′-GATCTACATGTTGTTGCTCCATTGTCTA CG-3′, C/EBP3 For; 5′-CAATATGCTTTGCAATAGGTTA TAAT-3′, C/EBP3 Rev; 5′-GATTATAACCTATTGCAAAG CATATT-3′.
| Chromatin immunoprecipitation assays
To identify interaction between specific transcription factors and DNA in vivo in the human FDC-SP gene promoter, ChIP assays were carried out using Ca9-22 cells. Confluent Ca9-22 cells in 100-mm culture dishes were stimulated by TNF-α (10 ng/ml) for 0, 3, 6, 12 and 24 hr, and then, the cells were fixed with 100 μl formaldehyde for 10 min to cross-link the protein-DNA complexes. The fixed cells were rinsed twice by a wash buffer (1 mM phenylmethylsulfonyl fluoride (PMSF) and complete protease inhibitor cocktail (Sigma-Aldrich) in the PBS (−)) on ice, collected by scrape and centrifuged for 5 min at 4°C. After the cells were resuspended by SDS buffer (1% SDS, 0.01 M EDTA, 0.05 M Tris-HCl, pH 8.1), lysate was sonicated to shear the protein-fragmentary DNA complexes. Sonicated cell supernatants were diluted in a 10-fold ChIP buffer (0.01% SDS, 1. % Triton X-100, 1.2 lM EDTA, 16.7 mM Tris-HCl, pH 8.9, 16.7 mM NaCl, 1 mM PMSF and complete protease inhibitor cocktail in ddH 2 O). The diluted supernatants were assigned input as a control which included nonspecific protein-DNA complexes and precleared with 80 μl of salmon sperm DNA/Protein A-Agarose (50% slurry) for 30 min at 4°C with gentle agitation. For the immunoprecipitation of protein-DNA complexes, 2 μg of rabbit polyclonal anti-YY1 antibody (ab38422, Abcam), GATA-6 (D61E4) XP ® Rabbit mAb (#5851, Cell
Signaling, Danvers, MA, USA), C/EBPβ (⊿198) (sc-746, Santa Cruz Biotechnology) and the appropriate normal rabbit IgG (sc-2027, Santa Cruz Biotechnology) were used for 300 μl of precleared supernatant, incubated overnight at 4°C with constant rotation. Sixty microliters of salmon sperm DNA/Protein A-Agarose (50% Slurry) was added for 1 hr at 4°C with rotation to collect the antibody/histone complexes and pellet agarose by gentle centrifugation (67 xg for 1 min). After removing the supernatant that contained unbound chromatin, the pellet was washed with 1 ml each of low-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 150 mM NaCl in ddH 2 O), high-salt buffer (0.1% SDS, 1% Triton X-100, 2 mM EDTA, 20 mM Tris-HCl, pH 8.1, 500 mM NaCl in ddH 2 O), LiCl buffer (0.25 M LiCl, 0.1% NP-40, 1% deoxycholate, 0.5 mM EDTA, 0.01 M Tris-HCl, pH 8.1 in ddH 2 O) and 1 ml of TE buffer (10 mM Tris-HCl, pH 8.1, 1 mM EDTA in ddH 2 O) twice. After the TE buffer was removed, Protein A-Agarose/antibody/chromatin complexes were resuspended in a 250 μl elution buffer (1% SDS and 0.1 M NaHCO 3 in ddH 2 O) and incubated at RT for 15 min with gentle rotation. After the spin down of the agarose beads, 20 μl 5 M NaCl was added to the supernatant for reverse cross-links, and 10 μl 0.5 M EDTA, 20 μl 1 M TrisHCl, pH 6.5 and 1 μl 10 mg/ml proteinase K were added to the degradation of the antibodies and proteins. DNA was recovered by phenol/chloroform/isoamylalcohol extraction and ethanol precipitation. The purified DNA was subjected to PCR amplification (1 cycle, 95°C for 3 min; amplification was carried out for 35 cycles, denature at 95°C for 15 s, anneal at 59 or 60°C for 15 s and extend at 72°C for 1 min; final extension was at 72°C for 1 min) mainly for the YY1, GATA, C/EBP2 and C/EBP3 sites within the human FDC-SP promoter using YY1 ChIP For; 5′-GTATTTGGTAGTTTCTAGGA-3′, YY1 ChIP Rev; 5′-GGCTTAAAGGCCTCTCCCCT-3′, GATA ChIP For; 5′-CATGTAAAGTGATAAACTTC-3′, GATA ChIP Rev; 5′-GGGGAATAACCAATGTTTAG-3′, C/EBP2 ChIP For; 5′-CCAGTAAAATGCTTAGAGGT-3′, C/EBP2 ChIP Rev; 5′-CTCCAAATTTTGTGTCTTGT-3′, C/EBP3 ChIP For; 5′-CTTAAGATTCCAGCACTATC-3′, C/EBP3 ChIP Rev; 5′-CTCACAATTTTTTCCTTTAC-3′ primers. KAPA Taq™ Extra HotStart was used for the PCR procedure, and the PCR products were separated on 2% agarose gels and visualized with ultraviolet light.
| Statistical analysis
Triplicate samples were analyzed for each experiment, and experiments were replicated to ensure the consistency of the responses to drugs. Significant differences between the control and treatment groups were determined using the one-way ANOVA.
